This is Genmab’s main focus for 2015
2014 was a year with full focus on daratumumab. 2015 will offer a number of interesting developments, but one thing in particular will catch CEO Jan van de Winkel.
BY BENJAMIN WERNER CHRISTENSEN
For the second year running, Genman has shown black numbers son its bottom line and 2014 proved a great year in many ways for the Danish biotech. 2015 has kicked off in great style as well, as the company presented very strong data for its myeloma contender daratumumab recently.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Danske: Genmab partner might accelerate launch
For abonnenter
Increased belief in Genmab’s potential blockbuster
For abonnenter
